Viking Therapeutics Investor Relations Material

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics to treat metabolic, endocrine and other central nervous system disorders. The company focuses on treatments for patients with liver disease, such as non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease and fibrosis; diabetes; thyroid diseases; and those suffering from adrenoleukodystrophy (ALD) and X-linked adrenoleukodystrophy (X-ALD). For NASH, it develops VK2809 - an orally available tissue and receptor-subtype selective agonist of thyroid hormone receptor beta (TRß) which is also in Phase IIb clinical trials for the treatment of patients with biopsy-confirmed NAFLD. Additional programs include VK0603 and VK0612 - orally available non-steroidal selective androgen receptor modulator drugs that are in Phase IIb clinical trials for the treatment of patients recovering from hip fractures; VK0612 is in Phase IIc clinical trials for type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Diego, California.